Ocular Rosacea Biome Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 22, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2026

Conditions
Ocular RosaceaAntimicrobial Resistance
Interventions
DRUG

Doxycycline 40 MG ( 20mg twice daily)

Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily

DRUG

Doxycycline 200 MG ( 100 mg twice daily)

200 mg dose doxycycline to be administered as 100mg twice daily

DRUG

Placebo

Placebo to be administered in tablet form twice daily

Trial Locations (1)

94143

University of California, San Farncisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER